01 Shift from qualitative imaging interpretation to quantitative biomarker-driven assessment The imaging biomarkers market is witnessing a transformation from subjective, visual interpretation of medical images to quantitative, data-driven evaluation. Earlier, imaging primarily relied on radiologists' expertise for visual assessment, which often varied across observers and lacked reproducibility. The shift toward quantitative imaging biomarkers integrates image-derived metrics such as texture, perfusion, and metabolism into measurable parameters. This transition enables standardized disease characterization, enhances diagnostic accuracy, and supports the development of imaging-based endpoints in clinical trials.
02 Shift from modality-specific imaging to integrated multi-omics platforms There is a growing transition from traditional single-modality imaging approaches (CT, MRI, PET) to integrated platforms that combine imaging biomarkers with genomic, proteomic, and metabolomic data. This shift reflects a broader move toward precision medicine, where imaging data is contextualized within molecular and biological frameworks to uncover deeper insights into disease mechanisms. The convergence of imaging and multi-omics analytics allows researchers to identify early predictive markers, improving patient stratification and therapeutic targeting in oncology and neurodegenerative diseases.
June 2026 Siemens Healthineers expanded its imaging biomarker and advanced imaging solutions portfolio with AI-enabled analysis tools. The developments support quantitative imaging, disease characterization, and personalized treatment planning across oncology and neurological applications.
March 2026 GE HealthCare expanded its precision imaging technologies with advanced AI-driven biomarker analysis capabilities. The solutions support clinicians and researchers in extracting quantitative insights from medical images for improved diagnosis and therapy monitoring.
January 2026 Philips expanded its image-guided healthcare portfolio with enhanced imaging analytics and biomarker solutions. The company focused on improving clinical decision-making through advanced visualization, AI integration, and quantitative imaging workflows.
October 2025 Roche expanded its digital pathology and biomarker analysis capabilities through advanced imaging technologies. The initiatives support personalized medicine by integrating imaging data with molecular insights for targeted treatment strategies.